Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
February 10, 2026

Dostarlimab for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency as of December 2025

MARA Rating Company February 10, 2026

Durvalumab / tremelimumab for untreated advanced or unresectable hepatocellular carcinoma as of August 2025

MARA Rating Company February 10, 2026

Abaloparatide for treating osteoporosis after menopause as of August 2024

MARA Rating Company February 10, 2026

Abemaciclib for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy as of September 2021

MARA Rating Company February 10, 2026

Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence as of July 2022

MARA Rating Company February 10, 2026

Abiraterone / zytiga for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer as of August 2021

MARA Rating Company February 10, 2026

Acalabrutinib for treating chronic lymphocytic leukaemia as of April 2021

MARA Rating Company February 10, 2026

Alecensa / alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer as of November 2024

MARA Rating Company February 10, 2026

Lemtrada / alemtuzumab for treating highly active relapsing-remitting multiple sclerosis as of May 2024

MARA Rating Company February 10, 2026

Alpelisib / piqray for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer as of August 2022

MARA Rating Company February 10, 2026